Literature DB >> 18322403

Lithium, a potential protective drug in Alzheimer's disease.

T Engel1, P Goñi-Oliver, E Gómez de Barreda, J J Lucas, F Hernández, J Avila.   

Abstract

Alzheimer's disease is characterized by the presence of two histopathological aberrant structures, the senile plaques and the neurofibrillary tangles. The main component of these tangles is the cytoskeletal protein tau in hyperphosphorylated form. Since a main tau kinase is glycogen synthase kinase 3 (GSK-3), the use of specific GSK-3 inhibitors, like lithium, could be a potential therapy in Alzheimer's disease. In this short article, we have done a review on tau phosphorylation in Alzheimer's disease and other tauopathies, and on the inhibition of kinases like GSK-3, involved in tau modification. 2008 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18322403     DOI: 10.1159/000113715

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  11 in total

1.  Activation of Glycogen Synthase Kinase-3 Mediates the Olfactory Deficit-Induced Hippocampal Impairments.

Authors:  Juan Hu; He-Zhou Huang; Xiang Wang; Ao-Ji Xie; Xiong Wang; Dan Liu; Jian-Zhi Wang; Ling-Qiang Zhu
Journal:  Mol Neurobiol       Date:  2014-11-05       Impact factor: 5.590

2.  NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy.

Authors:  Raquel Gómez-Sintes; José J Lucas
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

Review 3.  Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia.

Authors:  Edward D Huey; Nicole Armstrong; Parastoo Momeni; Jordan Grafman
Journal:  Expert Opin Ther Targets       Date:  2008-11       Impact factor: 6.902

Review 4.  Lithium and cognitive enhancement: leave it or take it?

Authors:  Eleftheria Tsaltas; Dimitris Kontis; Vasileios Boulougouris; George N Papadimitriou
Journal:  Psychopharmacology (Berl)       Date:  2008-09-10       Impact factor: 4.530

Review 5.  Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains.

Authors:  Valerie Askanas; W King Engel
Journal:  Acta Neuropathol       Date:  2008-10-31       Impact factor: 17.088

6.  Phosphorylation of neuronal survival factor MEF2D by glycogen synthase kinase 3beta in neuronal apoptosis.

Authors:  Xuemin Wang; Hua She; Zixu Mao
Journal:  J Biol Chem       Date:  2009-09-29       Impact factor: 5.157

7.  Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice.

Authors:  Illana Gozes
Journal:  EPMA J       Date:  2010-06-12       Impact factor: 6.543

8.  Enhanced lithium-induced brain recovery following cranial irradiation is not impeded by inflammation.

Authors:  Jordane Malaterre; Cameron S McPherson; Delphine Denoyer; Emily Lai; Jim Hagekyriakou; Sally Lightowler; Koishi Shudo; Matthias Ernst; David M Ashley; Jennifer L Short; Greg Wheeler; Robert G Ramsay
Journal:  Stem Cells Transl Med       Date:  2012-05-30       Impact factor: 6.940

9.  Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies.

Authors:  Miguel Medina; Juan Jose Garrido; Francisco G Wandosell
Journal:  Front Mol Neurosci       Date:  2011-10-05       Impact factor: 5.639

10.  Phosphorylation and O-GlcNAcylation of the PHF-1 Epitope of Tau Protein Induce Local Conformational Changes of the C-Terminus and Modulate Tau Self-Assembly Into Fibrillar Aggregates.

Authors:  François-Xavier Cantrelle; Anne Loyens; Xavier Trivelli; Oliver Reimann; Clément Despres; Neha S Gandhi; Christian P R Hackenberger; Isabelle Landrieu; Caroline Smet-Nocca
Journal:  Front Mol Neurosci       Date:  2021-06-17       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.